Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET
Company Participants
Susan Mesco - Head of Investor Relations
Frank Lee - Chief Executive Officer
Anthony Malloy - Chief Legal Counsel
Charles Reinhart - Chief Financial Officer
Jonathan Slonin - Chief Medical Officer
Conference Call Participants
David Amsellem - Piper Sandler
Gregory Renza - RBC Capital Markets
Gary Nachman - Raymond James
Leszek Sulewski - Truist Securities
Balaji Prasad - Barclays
Serge Belanger - Needham
Operator
Good day, and thank you for standing by. Welcome to the Q4 2023 Pacira BioSciences Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to your first speaker today, Susan Mesco, Head of Investor Relations. Please go ahead.
Susan Mesco
Thank you, and good morning, everyone. Welcome to today's conference call to discuss our fourth quarter and full year 2023 financial results. Joining me are Frank Lee, Chief Executive Officer; Tony Malloy, Chief Legal Counsel; and Charlie Reinhart, Chief Financial Officer; Jonathan Slonin, Chief Medical Officer, is also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or the Pacira website.
Before turning the call over to Frank, I'd like to mention that going forward in 2024, we will be shifting the timing of our quarterly calls to post market, with an expected start time of 4:30 p.m. Eastern Time.
With that, it is my pleasure to welcome Frank Lee.
Frank Lee
Well, thank you, Susan, and good morning, everyone. I'm excited to speak to you today as the new CEO of Pacira BioSciences. I was drawn to this organization because Pacira is the leader in non-opioid pain management. Pacira has market-leading products, a clear sense of purpose, a talented team and an unwavering commitment to transforming lives of patients by expanding access to opioid-sparing pain management.
I was especially inspired by the team's steadfast commitment to working with leading medical societies and patient organizations to get NOPAIN over the finish line. And this legislation is a real testament to Pacira's leadership.
It's been a busy and productive time since I joined the company last month, I've met with colleagues here in New Jersey and at our Science Center Campus in San Diego. I've also received valuable feedback on our culture and met with key stakeholders.